Skip to search formSkip to main contentSkip to account menu

AMG623 peptibody

Known as: A-623 
National Institutes of Health

Related topics

Related topics

2 relations

Narrower (1)

Blisibimod

Broader (1)

Recombinant Fusion Proteins

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
THU0387 Effects of Blisibimod, An Inhibitor of B Cell Activating Factor, On Patient Reported Outcomes and Disease Activity in Patients with Systemic Lupus Erythematosus
Background Blisibimod (A-623, AMG 623), a potent and selective inhibitor of B-cell activating factor (BAFF), was evaluated in the… 
2008
2008
S1124 Potential Usefulness of Predicting Stage of Colorectal Cancer By Fecal RNA Test
2006
2006
Optimal settings to adjust volatile end-tidal fraction: fresh gas flow or delivered fraction?: A-623
There were no significant differences in MAP, HR, SpO2 and BIS between the three groups. Incidence of side-effects was… 
2005
2005
Influence of acute elevation of intracranial pressure on duodenal motility activity and mucosal blood flow: A-623
Department of Anaesthesiology, University Hospital Aachen, Aachen, Germany Background and Aim of Study: In head injured patients… 
2004
2004
Postoperative analgesia management using a continuous popliteal sciatic nerve block in children: A-623
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)